Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.5% | -30.9% | 12.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.6% | 90.2% | 102.7% | 92.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -311.5% | -511.7% | -412.8% | -517.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -353.8% | -561.9% | -445.7% | -553.3% |
| EPS Diluted | -9.09 | -12.2 | -14.02 | -15.48 |
| % Growth | 25.5% | 13% | 9.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |